Steno Diabetes Center Copenhagen Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Gentofte Denmark (1932)

Organization Overview

First Clinical Trial
1993
NCT00311870
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Clinical Metabolic Physiology, Steno Diabetes Center Copenhagen | Kirsten Nørgaard | Kristine Færch | Lise Tarnow | Steno Diabetes Center | Steno Diabetes Center A/S | Steno Diabetes Center Copenhagen | Steno Diabetes Center Copenhagen, Clinical Metabolic Physiology | Steno Diabetes Center, Gentofte, Denmark | Steno Diabetes Center Sjaelland | Steno Diabetes Centes | Steno diabetic centre (SDCC)

Active Ingredients

Drugs in Phase 4 Trials (26)

allopurinol (zyloprim) (3 trials)

dapagliflozin (farxiga) (3 trials)

empagliflozin (jardiance) (2 trials)

glucagon (6 trials)

insulin aspart (Novolog) (2 trials)

insulin degludec (tresiba) (1 trial)

insulin detemir (Levemir) (3 trials)

insulin glargine (toujeo) (1 trial)

insulin human (humulin) (2 trials)

insulin lispro (humalog) (3 trials)

irbesartan (avapro) (2 trials)

linagliptin (tradjenta) (1 trial)

liraglutide (victoza) (6 trials)

lisinopril (zestril) (2 trials)

nisoldipine (sular) (1 trial)

paricalcitol (zemplar) (1 trial)

patiromer (veltassa) (1 trial)

protamine insulin (1 trial)

repaglinide (prandin) (2 trials)

semaglutide (Ozempic) (1 trial)

sitagliptin (januvia) (6 trials)

sodium chloride (2 trials)

spironolactone (aldactone) (4 trials)

sulodexide (Aterina) (1 trial)

telmisartan (micardis) (1 trial)

teriparatide (1 trial)

Drugs in Phase 3 Trials (5)

anakinra (Kineret) (2 trials)

esomeprazole (nexium) (1 trial)

ezetimibe (zetia) (1 trial)

melatonin (1 trial)

menaquinone (vitamin k2) (1 trial)

Drugs in Phase 2 Trials (4)

dasiglucagon (Zegalogue) (2 trials)

dextrose (1 trial)

exenatide (byetta) (1 trial)

metformin (glucophage) (1 trial)

Drugs in Phase 1 Trials (5)

bone marrow derived mesenchymal stem cells (1 trial)

gentamicin (garamycin) (1 trial)

glp-2 (1 trial)

meropenem (merrem) (1 trial)

vancomycin (Vancocin) (1 trial)

Drugs in Other Trials (13)

beta-hydroxybutyrate (1 trial)

curcumin (1 trial)

epinephrine (levophed) (1 trial)

epoetin (Epogen) (1 trial)

ethanol (1 trial)

gamma-amino-beta-hydroxybutyric acid (1 trial)

gastric inhibitory polypeptide (1 trial)

gip (1 trial)

gip (1-42) (1 trial)

glucose (1 trial)

secretin human (chirhostim) (1 trial)

sevelamer (renagel) (1 trial)

sodium butyrate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Albuminuria (Phase 4)

Arteriosclerosis (Phase 4)

Atherosclerosis (Phase 4)

Bone Diseases (Phase 4)

Cardiovascular Diseases (Phase 4)

Chronic Kidney Disease-Mineral and Bone Disorder (Phase 4)

Coronary Artery Disease (Phase 3)

Coronary Disease (Phase 3)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Foot (Phase 1)

Diabetic Nephropathies (Phase 4)

Diabetic Neuropathies (Phase 4)

Diabetic Retinopathy (Phase 3)

Foot Ulcer (Phase 1)

Heart Diseases (Phase 4)

Hyperkalemia (Phase 4)

Hypoglycemia (Phase 4)

Hypoxia (Phase 4)

Inflammation (Phase 4)

Kidney Diseases (Phase 4)

Kidney Failure, Chronic (Phase 3)

Myocardial Ischemia (Phase 3)

Osteoporosis (Phase 1)

Overweight (Phase 4)

Parasomnias (Phase 3)

Prediabetic State (Phase 2)

Renal Insufficiency, Chronic (Phase 4)

Retinal Diseases (Phase 3)

Sleep Disorders, Circadian Rhythm (Phase 3)

Sleep Wake Disorders (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 65
  • # of Trial APIs: 53